Navigation Links
Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
Date:3/4/2009

TSX Venture: QPT

EDMONTON, March 4 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "Company") a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced results from a study designed to investigate the effectiveness of its proprietary SL052 for photodynamic therapy (PDT) used in combination with immunotherapeutic agents in solid tumor animal models. The study, conducted by Dr. Mladen Korbelik at the BC Cancer Agency in Vancouver, demonstrated that SL052 increased the potency and effectiveness of immunotherapeutic agents when used in combination with SL052 PDT.

The results also confirmed that SL052 was an effective and well tolerated photosensitizer for PDT ablation of two highly tumorigenic, solid murine tumors. Further, the results demonstrated that photodynamic therapy generated direct local cytotoxicity and induced a systemic immune response, which could enhance its therapeutic effect on both primary tumors and metastases at distant sites.

The study tested several applications of SL052 and evaluated host recognition and immunological destruction of solid tumors. The results indicate the potential of SL052 PDT for use in combination with cancer vaccines to generate a superior immune response compared with vaccines alone. The study also revealed that SL052 PDT may be effectively combined with either single or multiple-complementary effectors of the host's immune response to substantially boost the frequency of permanent cures.

"The effects of immunotherapy can be amplified when combined with photodynamic therapy, potentially making immunophotodynamic therapy a superior systemic cancer treatment modality," said Thomas Woo, Vice President of Product Development at Quest.

SL052 is a non-toxic agent with broad potential to treat a variety of solid tumors using photodynamic (light activation) therapy or son
'/>"/>

SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... 2014  Decision Resources Group finds that the ... and Mexico currently faces ... approved agents, the anticipated label extension of Boehringer ... of emerging biologics will substantially increase the competitiveness ... IL-5 inhibitors will introduce a new dynamic to the ...
(Date:8/21/2014)... Calif. , Aug. 21, 2014  Four-dimensional ... and behaviors based on external stimuli such as ... to have a disruptive effect in multiple industries.  ... the business landscape by printing objects ranging from ... and automotive sectors. Logo - ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... has been recognized as one of the nation’s ... 5000 magazine for the 2nd consecutive year. Inc. ... 33rd annual Inc. 500|5000, an exclusive ranking of ... the most comprehensive look at the most important ...
Breaking Biology Technology:Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 2SoundConnect Returns on Inc. 5000 List of Fastest Growing Companies 3
... , ... ... ... ...
... ... ... ... ...
... , ... ... ... , ...
Cached Biology Technology:YM sees nimotuzumab license unaffected by civil claim against licensor 2YM sees nimotuzumab license unaffected by civil claim against licensor 3YM sees nimotuzumab license unaffected by civil claim against licensor 4YM sees nimotuzumab license unaffected by civil claim against licensor 5Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 2Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 3Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 4Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 5Concord Medical to Report Fourth Quarter and Fiscal Year 2009 Unaudited Financial Results on Thursday, March 18, 2010 6InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 2InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 3InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 4InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 5InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 6InterMune Announces Submission of MAA for Pirfenidone for the Treatment of Patients With IPF 7
(Date:8/21/2014)... improving the food intake, health and quality of life ... three projects at the University of Waterloo receiving close ... of Health Research (CIHR). , Professor Heather Keller, ... and a Schlegel research chair in nutrition and aging, ... many Canadians living in long-term care homes are poorly ...
(Date:8/21/2014)... finding that has implications for life in other extreme ... solar system, LSU Associate Professor of Biological Sciences Brent ... Foundation, or NSF, this week published a paper confirming ... lies 800 meters (2600 feet) beneath the surface of ... Given that more than 400 subglacial lakes and numerous ...
(Date:8/21/2014)... of the water window? It consists of radiations in ... absorbed by the water in biological tissues. New theoretical ... radiations within the water window. These could be the ... image of the biological samples or to be used ... the physical mechanism needed to efficiently generate the harmonic ...
Breaking Biology News(10 mins):Grants will fund landmark aging research at Waterloo 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 2800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 3800 meters beneath Antarctic ice sheet, subglacial lake holds viable microbial ecosystems 4Water window imaging opportunity 2
... New species are not just discovered in exotic localeseven ... new plants and animals. Academy scientists recently named a ... of fishes distantly related to sharks, from the coast ... species, the Eastern Pacific black ghostshark ( Hydrolagus melanophasma ...
... , , SEATTLE, Sept. ... leading provider of specialized reference laboratory and contract research services, today ... Terry M. Giles, providing for a $4 million loan (the "Loan") ... the Loan, on August 31, 2009, the Company also repurchased 2,391,906 ...
... , NEW YORK, Sept. 8 ... in its catalogue. , , ... http://www.reportlinker.com/p0131250/Carbon-Dioxide-Monitors.html , , This report ... of US$ by the following segments: End-tidal Carbon Dioxide (EtCO2) ...
Cached Biology News:New species of ghostshark from California and Baja California 2Pacific Biometrics Completes $4 Million Debt Financing 2Pacific Biometrics Completes $4 Million Debt Financing 3Pacific Biometrics Completes $4 Million Debt Financing 4Pacific Biometrics Completes $4 Million Debt Financing 5Reportlinker Adds Carbon Dioxide Monitors Report 2Reportlinker Adds Carbon Dioxide Monitors Report 3Reportlinker Adds Carbon Dioxide Monitors Report 4Reportlinker Adds Carbon Dioxide Monitors Report 5Reportlinker Adds Carbon Dioxide Monitors Report 6Reportlinker Adds Carbon Dioxide Monitors Report 7Reportlinker Adds Carbon Dioxide Monitors Report 8Reportlinker Adds Carbon Dioxide Monitors Report 9
... set the standard for sample concentration and drying. ... chamber uses a combination of centrifugal force, heat ... single run. , SC210A comes equipped with:, ... lasting chemical compatibility ...
... Acid Resistant SpeedVac Model SPD131DDA , Our ... SPD131DDA is designed to handle the rigors and ... slim design, digital display, dual independent timers, an ... chamber and vapor pathway. , , Adjustable ...
... Jouan RC Standard MB (For small quantities ... biology samples) of vacuum concentrator/centrifugal evaporator systems ... and biochemistry for rapid and safe concentration ... be expanded with pumps, different of cold ...
Monoclonal mouse antibody for immunihistology, clone AD12, Isotype IgG 1, purified, specific for rat pyruvatekinase type L, no cross-reactivities with other pyruvate kinase isoenzymes have been obser...
Biology Products: